Patents by Inventor Kyle S. Jones

Kyle S. Jones has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
    Publication number: 20250109203
    Abstract: Provided herein are polypeptides comprising at least one VHH domain that binds ?? TCR and a modified IL-2. Uses of the polypeptides are also provided.
    Type: Application
    Filed: January 4, 2023
    Publication date: April 3, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Bryan R. Becklund, Kyle S. Jones, Kaitlyn N. Robinson, Andrew M. Eckles, John C. Timmer, Brendan P. Eckelman
  • Gamma Delta T-Cell-Binding Polypeptides and Uses Thereof
    Publication number: 20250066477
    Abstract: Provided herein are VHH-containing polypeptides that bind ?? T-cells. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: January 4, 2023
    Publication date: February 27, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Bryan R. Becklund, Kyle S. Jones, Kaitlyn N. Robinson, Andrew M. Eckles, John C. Timmer, Brendan P. Eckelman
  • IgE binding proteins and uses thereof
    Patent number: 12234297
    Abstract: Provided herein are IgE-binding VHH domains, polypeptides, and proteins, and methods of using such IgE-binding polypeptides and proteins to modulate the biological activity of IgE.
    Type: Grant
    Filed: August 2, 2024
    Date of Patent: February 25, 2025
    Assignees: Phylaxis Bioscience, LLC, Inhibrx Biosciences, Inc.
    Inventors: Bryan R. Becklund, Kyle S. Jones, Andrew M. Eckles, Brendan P. Eckelman, Tony Dung-Ling Yao
  • CD33-Binding Polypeptides and Uses Thereof
    Publication number: 20250059279
    Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: August 2, 2024
    Publication date: February 20, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • Multivalent and multispecific OX40-binding fusion proteins
    Patent number: 12227584
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Grant
    Filed: August 10, 2021
    Date of Patent: February 18, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • IgE BINDING PROTEINS AND USES THEREOF
    Publication number: 20250019464
    Abstract: Provided herein are IgE-binding VHH domains, polypeptides, and proteins, and methods of using such IgE-binding polypeptides and proteins to modulate the biological activity of IgE.
    Type: Application
    Filed: August 2, 2024
    Publication date: January 16, 2025
    Inventors: Bryan R. Becklund, Kyle S. Jones, Andrew M. Eckles, Brendan P. Eckelman, Tony Dung-Ling Yao
  • Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same
    Patent number: 12195533
    Abstract: The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: January 14, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Quinn Deveraux, Kyle S. Jones, Rajay A. Pandit, John C. Timmer
  • Multivalent and multispecific 41BB-binding proteins
    Patent number: 12187804
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Grant
    Filed: December 16, 2022
    Date of Patent: January 7, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • Multivalent and Multispecific DR5-Binding Fusion Proteins
    Publication number: 20240376220
    Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.
    Type: Application
    Filed: April 4, 2024
    Publication date: November 14, 2024
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
  • CD33-binding polypeptides and uses thereof
    Patent number: 12084502
    Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: December 16, 2022
    Date of Patent: September 10, 2024
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • Multivalent and multispecific DR5-binding fusion proteins and methods of modulating immune cells
    Patent number: 11976126
    Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.
    Type: Grant
    Filed: August 5, 2021
    Date of Patent: May 7, 2024
    Assignee: Inhibrx, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
  • Multivalent and Multispecific 41BB-Binding Proteins
    Publication number: 20230416387
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Application
    Filed: December 16, 2022
    Publication date: December 28, 2023
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • CD33-Binding Polypeptides and Uses Thereof
    Publication number: 20230312716
    Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: December 16, 2022
    Publication date: October 5, 2023
    Applicant: Inhibrx, Inc.
    Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • PDL1-binding proteins
    Patent number: 11566078
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Grant
    Filed: October 15, 2019
    Date of Patent: January 31, 2023
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • CD33-binding polypeptides and uses thereof
    Patent number: 11560428
    Abstract: Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: January 24, 2023
    Assignee: Inhibrx, Inc.
    Inventors: Kyle S. Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • Multivalent and Multispecific OX40-Binding Fusion Proteins
    Publication number: 20220106397
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Application
    Filed: August 10, 2021
    Publication date: April 7, 2022
    Applicant: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • Multivalent and Multispecific DR5-Binding Fusion Proteins
    Publication number: 20220064318
    Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.
    Type: Application
    Filed: August 5, 2021
    Publication date: March 3, 2022
    Applicant: Inhibrx, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
  • Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms
    Patent number: 11117973
    Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF) and methods of treatment. More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: September 14, 2021
    Assignee: Inhibrx, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
  • Multivalent and multispecific OX40-binding fusion proteins
    Patent number: 11117972
    Abstract: This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: September 14, 2021
    Assignee: Inhibrx, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Hata, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan Becklund, Rajay Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • Multivalent and multispecific glucocorticoid-induced TNFR-related protein (GITR)-binding single-domain antibody fusion proteins and encoding nucleic acids
    Patent number: 10844129
    Abstract: This disclosure generally provides molecules that specifically engage glucocorticoid-induced TNFR-related protein (GITR), a member of the TNF receptor superfamily (TNFRSF). More specifically, the disclosure relates to multivalent and/or multispecific molecules that bind at least GITR.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: November 24, 2020
    Assignee: Inhibrx, Inc.
    Inventors: John C. Timmer, Kyle S. Jones, Amir Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman